Advances in prostate cancer imaging techniques and strategies

Focus on
First Online:

Keywords

Prostate Cancer Positron Emission Tomography Apparent Diffusion Coefficient Radical Prostatectomy Gleason Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Grönberg H. Prostate cancer epidemiology. Lancet. 2003;361(9360):859-64. Mar 8.CrossRefPubMedGoogle Scholar
  2. 2.
    Kumar RJ, Barqawi Al Baha, Crawford ED. Epidemiology of Prostate Cancer. Business Briefing: US Oncology Review 2004 http://www.touchoncologicaldisease.com/epidemiology-prostate-cancer-a2494-1.html.
  3. 3.
    Oehr P, Bouchelouche K. Imaging of prostate cancer. Curr Opin Oncol. 2007;19(3):259-64. May.CrossRefPubMedGoogle Scholar
  4. 4.
    Pallwein L, Mitterberger M, Pelzer A, Bartsch G, Strasser H, Pinggera GM, et al. Ultrasound of prostate cancer: recent advances. Eur Radiol. 2007 Oct 16 [Epub ahead of print]. DOI  10.1007/s00330-007-0779-7.
  5. 5.
    Zalesky M, Urban M, Smerhovský Z, Zachoval R, Lukes M, Heracek J. Value of power Doppler sonography with 3D reconstruction in preoperative diagnostics of extraprostatic tumor extension in clinically localized prostate cancer. Int J Urol. 2008;15(1):68-75. Jan.CrossRefPubMedGoogle Scholar
  6. 6.
    Nelson ED, Slotoroff CB, Gomella LG, Halpern EJ. Targeted biopsy of the prostate: the impact of color Doppler imaging and elastography on prostate cancer detection and Gleason score. Urology. 2007;70(6):1136-40. Dec.CrossRefPubMedGoogle Scholar
  7. 7.
    Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol. 2008;18(1):71-7. Jan.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Westphalen AC, Coakley FV, Qayyum A, Swanson M, Simko JP, Lu Y, et al. Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging. Radiology. 2008;246(1):177-84. Jan.CrossRefPubMedGoogle Scholar
  9. 9.
    Kim CK, Park BK, Lee HM, Kwon GY. Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3 T using a phased-array coil: preliminary results. Invest Radiol. 2007;42(12):842-7. Dec.CrossRefPubMedGoogle Scholar
  10. 10.
    Wang L, Mazaheri Y, Zhang J, Ishill NM, Kuroiwa K, Hricak H. Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. Radiology. 2008;246(1):168-76. Jan.CrossRefPubMedGoogle Scholar
  11. 11.
    Bouchelouche K, Oehr P. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. J Urol. 2008;179(1):34-45. Jan.CrossRefPubMedGoogle Scholar
  12. 12.
    Takahashi N, Inoue T, Lee J, Yamaguchi T, Shizukuishi K. The roles of PET and PET/CT in the diagnosis and management of prostate cancer. Oncology. 2007;72(3-4):226-33.CrossRefPubMedGoogle Scholar
  13. 13.
    Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, et al. [11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging. 2008 Jan 16; [Epub ahead of print]. DOI  10.1007/s00259-008-0716-2.
  14. 14.
    Eschmann SM, Pfannenberg AC, Rieger A, Aschoff P, Müller M, Paulsen F, et al. Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin. 2007;46(5):161-8.PubMedGoogle Scholar
  15. 15.
    Vavere AL, Kridel SJ, Wheeler FB, Lewis JS. 1-11C-Acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med. 2008 Jan 16; [Epub ahead of print]. DOI  10.2967/jnumed.107.046672.
  16. 16.
    Schiepers C, Hoh CK, Nuyts J, Seltzer M, Wu C, Huang SC, et al. 1-11C-Acetate kinetics of prostate cancer. J Nucl Med. 2008 Jan 16; [Epub ahead of print]. DOI  10.2967/jnumed.107.044453.
  17. 17.
    Manikandan R, Qazi HA, Philip J, Mistry R, Lamb GH, Woolfenden KA, et al. Routine use of magnetic resonance imaging in the management of T(1c) carcinoma of the prostate: is it necessary. J Endourol. 2007;21(10):1171-4. Oct.CrossRefPubMedGoogle Scholar
  18. 18.
    Shukla-Dave A, Hricak H, Scardino PT. Imaging low-risk prostate cancer. Curr Opin Urol. 2008;18(1):78-86. Jan.CrossRefPubMedGoogle Scholar
  19. 19.
    Fuchsjäger M, Shukla-Dave A, Akin O, Barentsz J, Hricak H. Prostate cancer imaging. Acta Radiol. 2008;49(1):107-20. Feb.CrossRefPubMedGoogle Scholar
  20. 20.
    Larson SM, Schöder H. Advances in positron emission tomography applications for urologic cancers. Curr Opin Urol. 2008;18(1):65-70. Jan.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Institute of Radiological SciencesUniversity of Milan, Unit of Nuclear Medicine, Hospital San PaoloMilanItaly

Personalised recommendations